Last reviewed · How we verify
DTG/3TC
DTG/3TC is a fixed-dose combination of dolutegravir (an integrase strand transfer inhibitor) and lamivudine (a nucleoside reverse transcriptase inhibitor) that blocks HIV replication by inhibiting two key viral enzymes.
DTG/3TC is a fixed-dose combination of dolutegravir (an integrase strand transfer inhibitor) and lamivudine (a nucleoside reverse transcriptase inhibitor) that blocks HIV replication by inhibiting two key viral enzymes. Used for HIV-1 infection in treatment-naïve and treatment-experienced adults, HIV-1 infection in adolescents and children (weight-based formulations).
At a glance
| Generic name | DTG/3TC |
|---|---|
| Also known as | Avridela, Dual therapy, Dovato |
| Sponsor | University of Nairobi |
| Drug class | Antiretroviral combination (integrase strand transfer inhibitor + nucleoside reverse transcriptase inhibitor) |
| Target | HIV integrase; HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease (HIV/AIDS) |
| Phase | FDA-approved |
Mechanism of action
Dolutegravir prevents HIV integrase from inserting viral DNA into the host genome, while lamivudine inhibits reverse transcriptase to prevent conversion of viral RNA to DNA. Together, they provide complementary antiretroviral activity against HIV-1 and HIV-2, reducing viral load and allowing immune reconstitution.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced adults
- HIV-1 infection in adolescents and children (weight-based formulations)
Common side effects
- Headache
- Nausea
- Diarrhea
- Fatigue
- Insomnia
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants (PHASE3)
- A Randomized Clinical Trial to Evaluate Solutions for the Management of Virologic Failure on TLD in Sub-Saharan Africa (NA)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) (PHASE2)
- A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy (PHASE3)
- Study of GS-3242 in Participants With HIV-1; Substudy-05 (PHASE1)
- DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children With HIV Infection Aged 2 to <15 Years Old (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DTG/3TC CI brief — competitive landscape report
- DTG/3TC updates RSS · CI watch RSS
- University of Nairobi portfolio CI